Can low-dose quetiapine (25–100 mg per day) cause akathisia?

Can Low-Dose Quetiapine Cause Akathisia?

Yes, low-dose quetiapine (25-100 mg/day) can cause akathisia, though the risk is substantially lower compared to most other antipsychotics.

Evidence from FDA Drug Labeling

The FDA label for quetiapine explicitly documents akathisia as an adverse reaction across multiple indications 1. In bipolar depression trials using 300-600 mg/day, akathisia occurred in 4% of quetiapine-treated patients versus 1% on placebo 1. While these studies used higher doses than typical "low-dose" use, they demonstrate quetiapine's capacity to cause akathisia even at therapeutic ranges where it's considered relatively benign for extrapyramidal symptoms.

Importantly, the FDA label notes that dystonic symptoms "can occur at low doses" of antipsychotics, though they occur more frequently with higher potency agents 1. The label groups akathisia with other extrapyramidal symptoms that can emerge during quetiapine treatment.

Guideline Recommendations

The 2025 INTEGRATE guidelines specifically identify quetiapine as having low propensity for akathisia, recommending it as a potential switch option when managing akathisia from other antipsychotics 2. The 2020 APA guidelines similarly suggest switching to another antipsychotic as one management strategy for akathisia 3, with quetiapine being among the preferred alternatives based on its EPS profile.

Research Evidence on Dose-Response Relationship

A 2023 systematic review and dose-response meta-analysis provides the most definitive answer: quetiapine carried negligible risk for akathisia across all examined doses, with a flat dose-response curve 4. This contrasts sharply with most other antipsychotics that showed either hyperbolic or monotonic increases in akathisia risk with higher doses.

A 2017 study in first-episode psychosis patients found quetiapine had an akathisia incidence of only 3.5%, comparable to olanzapine (3.6%) and dramatically lower than haloperidol (57%), risperidone (20%), or aripiprazole (18.2%) 5. This study used flexible dosing up to 800 mg/day, yet still demonstrated quetiapine's favorable profile.

Clinical Context and Caveats

Individual susceptibility matters. A 2010 case report documented acute akathisia in a 22-year-old female at just 150 mg/day of quetiapine, which resolved with dose reduction 6. The authors noted this occurred in someone "prone to develop EPS," highlighting that patient-specific factors can override general drug profiles.

A 2021 narrative review emphasizes that "even drugs which induce no other extrapyramidal side effects (such as clozapine, quetiapine, aripiprazole and cariprazine) may induce akathisia" 7. This underscores that no antipsychotic is completely free of akathisia risk.

Practical Algorithm for Assessment

When evaluating potential akathisia with low-dose quetiapine:

1. Verify the diagnosis: Look for subjective inner restlessness with objective purposeless movements that relieve tension
2. Consider alternative causes: Anxiety, agitation from underlying psychiatric condition, or other medications (SSRIs, SNRIs, stimulants can also cause akathisia) 7
3. Assess individual risk factors: Prior EPS history, younger age, male sex, and more severe baseline symptoms increase risk 5
4. Evaluate temporal relationship: Akathisia typically emerges within days to weeks of starting or increasing the dose

Management if Akathisia Occurs

Based on guideline recommendations 2, 3:

• First-line: Reduce quetiapine dose (if clinically feasible)
• If dose reduction insufficient: Add propranolol 10-30 mg two to three times daily 2
• Alternative adjunctive options: Benzodiazepines or beta-blockers 3
• If persistent: Consider switching to olanzapine (the only other antipsychotic with comparable low akathisia risk) 5

Bottom Line

While quetiapine has among the lowest akathisia risk of all antipsychotics—even at standard therapeutic doses—it is not zero risk. At low doses (25-100 mg/day) used off-label for insomnia or anxiety, akathisia remains possible but uncommon, particularly in individuals with prior EPS susceptibility. The flat dose-response curve suggests that if akathisia occurs with low-dose quetiapine, it's more likely related to individual patient factors than the dose itself.